Clinical Trials Browser

Phase 1 × Withdrawn × Temozolomide × Clear all

Brain Neoplasms, Glioblastoma

NCT03480867 2019-08-14

PARADIGMA

Phase 1 Withdrawn

CNS

Glioblastoma

NCT02831179 2017-09-28

Veliparib, Capecitabine, and Temozolomide in Patients With Advanced, Metastatic, and Recurrent Neuroendocrine Tumor

Phase 1 Withdrawn

DermatologicEndocrineGastrointestinalNET

Non functioning pancreatic endocrine tumor, Adrenal Cortex Neoplasms, Carcinoid Tumor, Vipoma, Glucagonoma, Insulinoma, Pheochromocytoma, Somatostatinoma, Zollinger-Ellison Syndrome, Carcinoma, Merkel Cell, Carcinoma, Medullary, Neuroendocrine Tumors, Multiple Endocrine Neoplasia Type 1, Multiple Endocrine Neoplasia Type 2a, Multiple Endocrine Neoplasia Type 2b

NCT00601614 2014-03-10

Vandetanib and Temozolomide in Treating Patients With Advanced Solid Tumors That Cannot Be Removed By Surgery

Phase 1 Withdrawn

Other solid neoplasm

Unspecified Adult Solid Tumor, Protocol Specific

NCT00904852 2009-05-20

Safety Study of the Combination of Tandutinib With Temozolomide and Bevacizumab After Radiation and Temozolomide in Patients With Newly Diagnosed With Glioblastoma Multiforme

Phase 1 Withdrawn

30 enrolled

CNS

Glioblastoma

Clinical Trials

A Study of Maprotiline in Combination With Tamoxifen and Temozolomide for Recurrent Glioblastoma

PARADIGMA

Veliparib, Capecitabine, and Temozolomide in Patients With Advanced, Metastatic, and Recurrent Neuroendocrine Tumor

Vandetanib and Temozolomide in Treating Patients With Advanced Solid Tumors That Cannot Be Removed By Surgery

Safety Study of the Combination of Tandutinib With Temozolomide and Bevacizumab After Radiation and Temozolomide in Patients With Newly Diagnosed With Glioblastoma Multiforme